Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.

Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP.

Clin Cancer Res. 2004 Oct 15;10(20):6847-54.


Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.

Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP.

Clin Cancer Res. 2001 Jul;7(7):1894-900.


Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.

Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5.


Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels.

Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP, Gescher A.

Clin Cancer Res. 2001 May;7(5):1452-8.


Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents.

Plummer SM, Hill KA, Festing MF, Steward WP, Gescher AJ, Sharma RA.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1295-9.


Chemotherapeutic potential of curcumin for colorectal cancer.

Chauhan DP.

Curr Pharm Des. 2002;8(19):1695-706. Review.


Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis.

Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40.


Phase II trial of curcumin in patients with advanced pancreatic cancer.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R.

Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024.


Clinical studies with curcumin.

Hsu CH, Cheng AL.

Adv Exp Med Biol. 2007;595:471-80. Review.


Curcumin: the story so far.

Sharma RA, Gescher AJ, Steward WP.

Eur J Cancer. 2005 Sep;41(13):1955-68. Review.


Pharmacokinetics and pharmacodynamics of curcumin.

Sharma RA, Steward WP, Gescher AJ.

Adv Exp Med Biol. 2007;595:453-70. Review.


Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY.

Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.


Dose escalation of a curcuminoid formulation.

Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE.

BMC Complement Altern Med. 2006 Mar 17;6:10.


Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action.

Garg R, Gupta S, Maru GB.

Carcinogenesis. 2008 May;29(5):1022-32. doi: 10.1093/carcin/bgn064. Epub 2008 Mar 4.


Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences.

Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ.

Clin Cancer Res. 2006 May 1;12(9):2944-50.


Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability.

Irving GR, Howells LM, Sale S, Kralj-Hans I, Atkin WS, Clark SK, Britton RG, Jones DJ, Scott EN, Berry DP, Hemingway D, Miller AS, Brown K, Gescher AJ, Steward WP.

Cancer Prev Res (Phila). 2013 Feb;6(2):119-28. doi: 10.1158/1940-6207.CAPR-12-0281. Epub 2012 Dec 11.


Systemic delivery of curcumin: 21st century solutions for an ancient conundrum.

Bisht S, Maitra A.

Curr Drug Discov Technol. 2009 Sep;6(3):192-9. Epub 2009 Sep 1. Review.


Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.

Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE.

Cancer Prev Res (Phila). 2011 Mar;4(3):354-64. doi: 10.1158/1940-6207.CAPR-10-0098. Erratum in: Cancer Prev Res (Phila). 2012 Dec;5(12):1407. Dosage error in article text.


Curcumin for chemoprevention of colon cancer.

Johnson JJ, Mukhtar H.

Cancer Lett. 2007 Oct 8;255(2):170-81. Epub 2007 Apr 19.

Items per page

Supplemental Content

Write to the Help Desk